Quote | Immatics N.V. (NYSE:IMTX)
Last: | $15.05 |
---|---|
Change Percent: | -1.7% |
Open: | $15.75 |
Close: | $15.05 |
High: | $16.5 |
Low: | $14.62 |
Volume: | 95,850 |
Last Trade Date Time: | 07/03/2020 04:56:45 pm |
News | Immatics N.V. (NYSE:IMTX)
2024-04-02 14:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-21 07:12:53 ET More on Immatics Immatics: Pioneering TCR Therapies In The Fight Against Cancer Seeking Alpha’s Quant Rating on Immatics Historical earnings data for Immatics Financial information for Immatics Read the full article on ...
Message Board Posts | Immatics N.V. (NYSE:IMTX)
Subject | By | Source | When |
---|---|---|---|
znewcar1: $IMTX 27% v4,9M c9.33 f76,67M h9.98 ML5.9 | znewcar1 | investorshangout | 05/02/2023 8:37:44 PM |
$IMTX: IMA203 update | FACT-MASTER | investorshub | 05/02/2023 1:09:54 PM |
$IMTX MomentumIts gaining | Solarfuture | investorshub | 05/01/2023 9:52:32 PM |
$IMTX Price trading last up | FACT-MASTER | investorshub | 05/01/2023 3:14:08 PM |
must see | FACT-MASTER | investorshub | 05/01/2023 12:56:02 PM |
News, Short Squeeze, Breakout and More Instantly...
Immatics N.V. Company Name:
IMTX Stock Symbol:
NYSE Market:
2024-04-02 14:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objective response rate with median duration of response not reached at median follow-up of 14.4 months; IMA203 was well tolerated Registration-enabling randomized Phase 2/3...
Caleres Inc. (CAL) is expected to report $0.86 for Q4 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-12-31 Dermata Therapeutics Inc. (DRMA) is expected to report for Q4 2023 Core & Main Inc. Class A (CNM) is expected to report $0.34 for Q4 2024 Wi...